Results ahead of guidance and a first vaccine on sale
ECO Animal Health Group plc (LSE:EAH) reported full-year results on 15 July 2026 for the year ended 31 March 2026 that came in ahead of the board's own guidance. Revenue rose 10% to £87.5m, beating the £85.6m indicated in a March 2026 trading update, while profit before tax increased 35% to £5.4m. Alongside the numbers, the company confirmed that its first poultry vaccine, ECOVAXXIN MS, had been commercially launched in the European Union on 30 June 2026, with a first customer order received shortly afterwards.
What the company does
ECO Animal Health develops and sells animal health products, with a long-established franchise in Aivlosin, an antibiotic used in pigs and poultry. It sells through a global network, with major markets in North America, Latin America, China and Japan, and South and Southeast Asia. In recent years it has invested heavily in R&D to build a vaccine portfolio.
Latest developments
ECOVAXXIN MS, aimed at Mycoplasma synoviae in poultry, received a positive opinion from the European Medicines Agency in November 2025 and EU marketing authorisation in December 2025. A second product, ECOVAXXIN MG, received what was described as a favourable safety assessment from the US Department of Agriculture in March 2026, with US approval targeted by the end of calendar 2026 but not yet confirmed. Management has said up to nine products could gain US or EU approval over the next five to six years, including a pig vaccine targeted for around 2028.
Regionally, North American revenue rose 22% to £26.1m and Latin America grew 15% to £18.8m. China and Japan increased 5% to £24.1m, while South and Southeast Asia fell 7% and Europe slipped 2%.
Financial and dividend picture
Gross margin improved to 48.6% from 45.1%, and the board described the improvement as sustainable. Adjusted EBITDA rose 16% to £8.5m and earnings per share increased 31% to 3.26p. Cash stood at £25.4m at the year end, of which £9.8m was held outside China. No dividend was declared, with the company prioritising reinvestment in R&D. For the current financial year, the board said it expected performance in line with market expectations.
The share price was about 87.5p on 22 July 2026, roughly 25% below a 52-week high of 115p set in February 2026.
Sector and index context
ECO Animal Health is a healthcare constituent of the FTSE AIM All Share Index. The animal health sector is shaped by livestock economics, regulation of antibiotic use and growing demand for preventive products such as vaccines. A shift towards vaccines could reduce dependence on a single antibiotic franchise over time.
Key risks
Regulatory approvals remain uncertain and can be delayed. A meaningful share of cash is held in China, which can limit flexibility. Weaker sales in some Asian and European markets show the business is exposed to regional livestock cycles, disease outbreaks and currency swings. Early vaccine sales may take time to scale.
What to watch next
Investors will watch for a US decision on ECOVAXXIN MG by the end of 2026, order flow for ECOVAXXIN MS and interim results, which have typically been published in late November or early December. Any update on how quickly vaccine revenue builds, and whether the firmer gross margin holds through the first half of the new financial year, is likely to shape sentiment towards the shares as the company moves from a single-franchise business towards a broader portfolio.






Please wait processing your request...